Get started
A signal so bullish it might make you $CMKey Stats P/E Ratio: 12.86 (below the sector average of 11.8) Dividend Yield: 3.89%, with consistent payout history Next Earnings Date: Feb 27, 2025 Recent Upgrade: Barclays raised target to $98 (Nov 30, 2024) Revenue Growth: 7% YoY Top 3 Technical Reasons for Bullish Bias Breakout Zone Approaching: Price testing $94, a critical resistance from August. Break here unlocks $100+. Golden Crossover Incoming: The 50-day SMA is edging toward a crossover with the 200-day SMA—classic bullish signal. Strong RSI Rebound: RSI at 58, climbing but not yet overbought, suggesting more room to run. Top 3 Fundamental Reasons for Bullish Bias Undervalued vs Peers: Low P/E and price-to-book ratio make CM a bargain in the Canadian banking sector. Dividends Make It Rain: 3.89% yield at this valuation is a fortress for income investors, even if growth slows. Economic Recovery Boost: Canada's improving GDP and housing markets directly benefit CM’s retail and mortgage banking units. Potential Paths to Profit 1️⃣ Lowest Risk: Buy shares outright and collect that juicy dibadend while waiting for the move to $101. 2️⃣ Options Play: Buy LEAPs. Disclaimer: We are not a brokerage or investment firm. We do not offer financial advice or investment advice and/or signals. This is not certified financial education. We offer access to the daily thought process of an individual and his experiences. We do not offer refunds. All sales are final.
TSX:CMLong
by ChartVZN
Cineplex $CGX making a comeback!Key Stats Price: $12.63 (as of Dec 1, 2024) Market Cap: 798M CAD Revenue (TTM): 1.39B CAD (+1.95% YoY) P/S Ratio: 0.78 Next Earnings Date: February 2025 Top 3 Technical Reasons (Bullish Bias) Strong support near $12.50: CGX has been testing this zone, forming a solid base with potential for a bounce. Breakout Watch: A bullish ascending triangle is forming, signalling a possible breakout towards $16. Volume Uptick: Recent trading days show increased volume on up moves—buyers are stepping in. Top 3 Fundamental Reasons (Bullish Bias) Revenue Growth Resilience: Despite sector struggles, Cineplex's revenue rose 1.95% YoY, outpacing some peers. Deep Value Play: A P/S ratio of 0.78 highlights undervaluation compared to broader industry averages. Canada’s Cinematic Recovery: Increased box office sales as tentpole releases and audience confidence return post-pandemic. Potential Paths to Profit Low-risk: Buy shares outright and aim for the $16 target. Options Play: Consider $15 strike calls expiring in May 2025 for leverage. Disclaimer: We are not a brokerage or investment firm. We do not offer financial or investment advice. This is not certified financial education. All sales are final, and refunds are not offered.
TSX:CGXLong
by ChartVZN
Get ready for the upsideThe stock appears to be in a pullback phase. I anticipate it will find support around the previous monthly highs, keeping prices contained between that level and the anchored VWAP (Volume-Weighted Average Price) from the recent swing high. Once the price advances back up toward this anchored VWAP and experiences a slight pullback, the key will be to break through it. If the stock establishes a pattern of higher highs and higher lows on the 30-minute chart, it would strengthen the bullish outlook.
TSX:PPLLong
by AnotherBrian
$BHC BUYS. Good time for pharma!Key Stats: Market Cap: $4.4B Revenue (TTM): $11.82B EBITDA Margi Debt: $29.05B (High, but manageable with recent restructuring efforts) Technical Indicators: 1️⃣ 50-Day and 200-Day Moving Average Crossover: BHC is trending above its 200-day moving average, showing long-term bullish momentum. 2️⃣ RSI Neutral : No signs of overbought territory, providing room for further upside without a pullback. 3️⃣ Strong Support Zone: Key support held firmly, suggesting bulls are defending this level. Fundamental Indicators: 1️⃣ Valuation Play: BHC is undervalued relative to its industry, despite consistent revenues of $11.82B annually. The EV/EBITDA ratio of 8.1 confirms a bargain price. 2️⃣ Operational Efficiency: EBITDA margins at 34.5% and an operating cash flow of $1.01B indicate strong cash-generating ability, even under high debt loads. 3️⃣ Catalyst Potential: Patent dispute resolutions and potential drug approvals could act as significant tailwinds for revenue growth and investor sentiment. Potential Path to Profit: 1️⃣ Lowest Risk: Buy shares outright at current levels. Disclaimer: We are not a brokerage or investment firm. This is not financial advice. All sales are final.
TSX:BHCLong
by ChartVZN
Bullish on $BMO and Canadian banksKey Stats Market Cap: CAD 97 billion P/E Ratio: 15.45 (Sector avg: 11.8) Dividend Yield: 4.6% (reliable passive income) Next Earnings Date: Dec 5, 2024 Last Upgrade: Maintained "Buy" by RBC with price target CAD 155 (Dec 2024). Technical Reasons for Bullish Outlook Golden Cross Formation: The 50-day moving average recently crossed above the 200-day moving average, indicating long-term bullish momentum. Strong Support Zone: BMO has consistently rebounded off demand levels, forming a solid base for upward price action. Positive Divergence in RSI: RSI trending higher despite sideways price movement suggests accumulation by institutional players. Fundamental Reasons for Bullish Outlook Interest Rate Environment: Higher interest rates boost net interest margins, directly benefiting BMO’s profitability. U.S. Market Expansion: Strategic growth in the U.S. through recent acquisitions increases revenue diversification and growth potential. Strong Dividend Track Record: BMO's 4.6% yield underscores stability, appealing to both growth and income-focused investors. Potential Paths to Profit Option 1: Lowest Risk - Buy Shares Purchase shares at the current price. Collect quarterly dividends while riding the momentum toward CAD 160. Option 2: Medium Risk - Buy Call Options Consider June 2025 $130 calls (estimated premium: CAD 5.00). Leverage potential for higher returns with manageable upfront risk. Option 3: Income Boost - Covered Calls Buy shares and sell March 2025 $140 calls. Capture premium income while profiting up to CAD 140 if called. Disclaimer We are not a brokerage or investment firm. We do not offer financial advice or investment signals. This is not certified financial education. We offer access to the daily thought process of an individual and his experiences. We do not offer refunds. All sales are final.
TSX:BMOLong
by ChartVZN
Buy $ATD if you want your portfolio to reach ATHKey Stats: Current Price: CAD 81.91 (as of Dec 1, 2024) Market Cap: CAD 77.65B P/E Ratio: 22.58 1-Year Performance: +7.2% Next Earnings Date: March 25, 2025 Top 3 Technical Reasons ATD Will Rise: Breakout Momentum: ATD recently broke out from a consolidation phase, with price reclaiming its 20-day and 50-day moving averages. Classic bullish signal. Volume Surge: Increased trading volume over the past week confirms institutional accumulation. Targeted Price Action: Resistance near CAD 82.50 is within range, and if cleared, a swift move toward CAD 92 is probable. Fibonacci projections align with this target. Top 3 Fundamental Reasons ATD Will Rise: Resilient Earnings: Despite a minor Q3 miss (-3.18%), earnings per share growth remains solid. Analyst expectations for Q4 (CAD 1.08 EPS) are promising. Defensive Retail Leader: With a network of 15,000+ convenience stores, ATD thrives during economic uncertainties due to its essential goods model. Valuation Looks Good: A P/E of 22.58 is reasonable given ATD’s growth trajectory and strong cash flow. Market cap stability also indicates sustained investor confidence. Potential Paths to Profit: Buy Shares: The most straightforward, lowest-risk approach. Call Options: Consider March 2025 CAD 85 strike calls. Leverage upside while capping downside risk. Swing Trade: Look for pullbacks near CAD 80 for a favorable risk-reward entry point. Disclaimer: We are not a brokerage or investment firm. We do not offer financial advice or investment signals. This is not certified financial education. We share an individual's trading ideas. No refunds. All sales final.
TSX:ATDLong
by ChartVZN
DECISIVE DIVID CORP | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # DECISIVE DIVID CORP - Triple Formation * Support=0 | Trend, Behaviour & Entry Principle * Retracement | 012345 | Subdivision 1 * Pennant Structure At 8.30 & 6.87 | Subdivision 2 - Double Formation * Wedge Structure | Failed Target | Subdivision 3 * Neckline Area at 6.00 Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell
TSXV:DEShort
by TradePolitics
Chartvzn Analysis: Canadian Imperial Bank of Commerce (CM)b]Key Stats Market Cap: CAD 55.6B P/E Ratio: 12.89 (Moderately undervalued compared to industry averages) Dividend Yield: 5.91% (Solid for income investors) Revenue Growth: 2.58% YoY (Recent FY revenue: CAD 21.31B) Next Earnings Date: December 7, 2024​ Technical Reasons for Upside Bullish Hammer Formation: Recent price action carved out a hammer candlestick on November 20, signaling strong buyer support at lower levels. Ascending Channel Support: The stock is hugging the bottom of a long-term bullish channel, offering an attractive risk-reward entry. Oversold RSI Recovery: Daily RSI bounced from oversold levels (38), aligning with potential upward momentum. Fundamental Reasons for Upside Strong Dividend Play: A consistent 5.91% yield positions CM as a defensive pick amid market volatility, attracting income investors. Positive Analyst Sentiment: Recent upgrades, with price targets ranging from CAD 94 to CAD 97, signal optimism in CM’s performance. Improved Loan Portfolio Risk: Management’s risk transfer initiatives are reducing exposure to corporate defaults​. Potential Paths to Profit Low Risk: Accumulate shares below CAD 93. Enjoy the dividends and hold until the target is hit. Options Play: Buy Dec 20, 2024 CAD 94 calls (~CAD 2.10 premium). Attractive theta decay under low volatility. Pair Trade: Hedge with short positions in a weaker Canadian bank like Laurentian (LB). Disclaimer: We are not a brokerage or investment firm. We do not offer financial advice or investment advice and/or signals. This is not certified financial education. We offer access to the daily thought process of an individual and his experiences. We do not offer refunds. All sales are final.
TSX:CMLong
by ChartVZN
NRX looks great at these levelsKey Stats Market Cap: $14.5M 52-Week Range: $1.10 - $7.33 Short Interest: 6.68%, with days to cover at 3.51 RSI (14): 41 (leaning towards oversold territory) Technical Reasons for Upside Price Rejection at Key Support: NRXP has been hugging the $1.20–$1.25 range, with consistent rejection at $1.10. This suggests bottoming out and a bounce in the cards. Volume Divergence: Recent days showed a pick-up in volume as price consolidated near support, signaling potential accumulation. Oversold Indicators: With an RSI of 41, it's creeping into the “bargain bin” zone. A reversal toward neutral RSI could drive price recovery. Fundamental Reasons for Upside Hope Therapeutics Expansion: A subsidiary of NRXP just secured FWB:30M in funding for ketamine clinic growth, projecting $100M revenue by 2025. That's a significant narrative shift for such a small-cap stock. Potential FDA Developments: Investors are hopeful for updates on NRXP's pipeline, particularly related to its ketamine-based treatments. Speculation often drives micro-cap biotech moves. Sector Sentiment: The broader biotech sector is seeing renewed interest as year-end rotations favor risk-on assets. NRXP could ride this tide. Potential Paths to Profit Buy the Shares (Lowest Risk): Just grab the stock and wait for the price to hit your target of $1.19. Simple and effective. Options Play: Look for near-term calls (if available) with a strike at $1 or slightly OTM. Biotech pops can be explosive, so a small investment here could yield outsized returns. Swing Trade Strategy: Buy on dips near $1.15 and sell into strength around $1.18–$1.19. Repeat if volatility allows. Disclaimer: We are not a brokerage or investment firm. We do not offer financial advice or investment advice and/or signals. This is not certified financial education. We offer access to the daily thought process of an individual and his experiences. We do not offer refunds. All sales are final.
TSXV:NRXLong
by ChartVZN
well....lets try thisPOET....on the cusp of technological greatness....if anyone can understand what they have to offer! I'm a chart idiot...have had some success and failures. I'm not a fan of gaps unless they follow news. POET has a couple gaps as it ripped out the gate. I'm on CEO.ca...the banter there would make your eyes bleed by people who think this is ready t take over for Microsoft or something like that. It's a slick set up, it's possible they can get some major traction...but it's more possible right now it's too early. I'm watching it for closing those gaps before jumping onboard. I'll refresh weekly if I remember. Anyone else out there working this potential gem?
TSXV:PTKLong
by Honkytime